AbbVie announced the acquisition of Capstan Therapeutics for up to $2.1 billion, gaining access to Capstan’s in vivo CAR-T platform and its phase 1 autoimmune program targeting CD19. Capstan’s approach uses targeted lipid nanoparticles for in vivo cell engineering, representing a novel therapeutic modality in immunology and oncology. Abbott intends to leverage this acquisition to bolster its immunology and inflammation pipeline with next-generation cell therapies.